Novartis broadens BRAF/MEK cancer combo use, winning tumor-agnostic approval in patients 6 and up - Endpoints News

Novartis nabbed another FDA win for its Tafinlar and Mekinist cancer combo, this time broadening its label quite widely. US regulators greenlighted the therapy for any solid tumor in patients with BRAF V600E mutations whose cancers are unresectable or metasta…

While oligonucleotides, a wide variety of synthetically modified RNA or RNA/DNA hybrids that bind to a target RNA sequence to alter RNA and/or protein expression, have been winning approvals in recen… [+571 chars]

full article...